Company Overview and News

5
Permian Auction Doubles 2008 Record with near Billion-Dollar Sale

2018-09-07 rigzone - 1
(Bloomberg) -- The price to access unexplored shale assets on the New Mexico side of the Permian Basin soared to $95,001 an acre in a federal government auction, a record high for North America’s biggest oil field.
XOM RSPP CVX DVN EOG

20
Pipeline Pinch Plagues Permian Play: Winners and Losers

2018-09-04 zacks - 1
For the longest time, Permian Basin has been the golden shale area of the United States. Crude output from the Permian has been on fire with the United States becoming the world’s numero uno oil producing country in 2017. While production in the Permian is soaring, its takeaway capacity in the region is not increasing to that proportion. This mismatch presents a massive opportunity to midstream companies as well as the refining players.
APA NBL XOM CXO PE VLO MPC EOG TSNU ETP DK RSPP CVX HFC EGN PAA OXY TSN FANG

2
Concho Resources: Permian Basin's Biggest Oil Producer Will Get Even Bigger

2018-09-01 seekingalpha
Concho Resources has become the biggest and one of the most active drillers at the Permian Basin, the premier US shale oil play.
7018 CME RSPP CXO

2
Why Is Concho Resources (CXO) Down 2.4% Since Last Earnings Report?

2018-09-01 zacks
A month has gone by since the last earnings report for Concho Resources (CXO - Free Report) . Shares have lost about 2.4% in that time frame, underperforming the S&P 500.
RSPP CXO

7
Diamondback Energy: A Bit About The Acquisition

2018-08-25 seekingalpha
Energen has been facing pressure from activist investors Carl Icahn and Keith Meister who have been pushing for the company's sale.
APA RSPP CTLR EGN CXO CLR FANG

3
[Press] Diamondback Eyes Synergies in the Permian Basin with Energen Acquisition

2018-08-21 oilvoice
US oil and gas producer Diamondback Energy's $9.2 billion acquisition of rival player Energen this week should generate significant synergies and improved overall production on operations in the prolific Permian Basin shale play, according to analysis by Rystad Energy. This deal, coming hot on the heels of Diamondback's $1.25 billion acquisition of private player Ajax Resources, propels Diamondback to the top of the list of Permian M&A spenders in 2018.
OPHR RSPP CXO FANG

3
[Press] Rystad Energy: Diamondback Eyes Synergies in the Permian Basin with Energen Acquisition

2018-08-21 oilvoice
US oil and gas producer Diamondback Energy's $9.2 billion acquisition of rival player Energen this week should generate significant synergies and improved overall production on operations in the prolific Permian Basin shale play, according to analysis by Rystad Energy. This deal, coming hot on the heels of Diamondback's $1.25 billion acquisition of private player Ajax Resources, propels Diamondback to the top of the list of Permian M&A spenders in 2018.
OPHR RSPP CXO FANG

3
Top Permian Basin Stocks Are Cheap: 4 Jefferies Favorites to Buy Now

2018-08-20 247wallst - 1
The price of West Texas Intermediate crude has dropped almost 12% from highs posted in June, and some of the very best stocks in the energy sector have been hit hard as fast money started to move out of the exploration and production stocks. Despite some surges in global supply though, reserves are not being replaced at close to what they were in the past. In addition, some of the infrastructure product transportation issues from regions like the Permian Basin may be resolved earlier than some thought.
ECA ECN CPE RSPP CXO PE ECA

5
Global Energy Advisory – 17th August 2018

2018-08-17 oilprice
The Permian once again reaffirmed its status as the star shale play in the United States after Diamondback announced it had inked a merger deal worth $9.2 billion with peer Energen. This is the second Permian deal for Diamondback within a week, after it announced the acquisition of Ajax Resources for $1.2 billion.
BLT BHP RSPP BHPBF EGN BBL BHP CXO BHPLF

63
Cracks In Global Economy Weigh On Oil Markets

2018-08-17 oilprice
Tom majored in International Business at Amsterdam’s Higher School of Economics, he is now working as news editor for Oilprice.com.
BLT XOM HES BHPBF CXO BP BHP RSPP EGN BBL TSLA BHP BHPLF EQNR FANG

20
Diamondback Buys Energen for $9.2B in the Permian Frenzy

2018-08-16 zacks - 2
Indeed, Permian deal frenzy has swept the U.S. oil industry of late, bringing about a wave of consolidation in the prolific shale play. The latest energy company to join the bandwagon is Diamondback Energy, Inc. (FANG - Free Report) , which is set to acquire Energen Corporation (EGN - Free Report) in a mega $9.2-billion deal, in a bid to bolster its Permian presence. Post the announcement of the deal, shares of Energen increased more than 2.
NBL BLT XOM BHPBF REN PE CXO LLEX AXAS OAS BHP RSPP CVX EGN BBL BHP MRO JAG BHPLF OXY FANG

3
Large investment groups throw weight behind oil rally

2018-08-15 worldoil
HOUSTON and NEW YORK (Bloomberg) -- The recovery in the oil industry is attracting some of the most recognized billionaires in money management.
GILD KMI RSPP DVN KMR MPC CVB KMRFZ

3
Diamondback’s $9.2B Energen Deal Creates Third-Largest Permian Player

2018-08-15 oilprice
Tsvetana is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing for news outlets such as iNVEZZ and…
RSPP CXO FANG

6
Deal frenzy swells with Diamondback's $8.4-billion shale buyout

2018-08-15 worldoil
NEW YORK and HOUSTON (Bloomberg) -- Diamondback Energy’s agreement to buy Energen in an $8.4-billion all-stock deal makes it official: The long-awaited Permian basin buying spree has arrived, promising to shake up the U.S. shale industry.
LG BP RSPP BP CXO BPAQF BP.A BP.B FANG

8
Billionaires Throw Weight Behind Oil Rally

2018-08-15 rigzone - 1
(Bloomberg) -- The recovery in the oil industry is attracting some of the most recognized billionaires in money management.
SLB FB GILD DVN MPC KMI RSPP CVX SCL SLB KMR CVB KMRFZ

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 74978Q105